Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WATCHMAN vs Rivaroxaban for Stroke Prevention in AF
NCT02549963Phase 4Unknown
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Atrial fibrillation (AFib) (2 arms). Primary endpoint: Combined endpoint at 2 years. Status: unknown.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02549963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549963.